Zydus Lifesciences Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 1,27,988 shares,. Its Average Traded Price (ATP) is ₹1201.44, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 120 @ ₹1202.90.
Zydus Lifesciences has an upper circuit limit of ₹1311.20 and a lower circuit limit of ₹1072.80. The total value traded stands at ₹15.38 CR, and the delivery percentage for the day is 61.15%.
The stock is currently traded with a market lot size of 1. Zydus Lifesciences also offers a dividend yield of 0.08%.
Zydus Lifesciences Share Price Chart
Zydus Lifesciences Share Key Metrics
Volume
1.28 L
Market Cap
118902.46 CR
LTQ@LTP
120@1202.90
ATP
1201.44
Var Margin
13.4 %
Circuit Range
1072.8-1311.2
Delivery %
61.15 %
Value
15.38 CR
ASM/GSM
No
Market Lot
1
Zydus Lifesciences Resistance and Support
Pivot 1193.43
Resistance
First Resistance
1205.76
Second Resistance
1219.53
Third Resistance
1231.86
Support
First Support
1179.66
Second Support
1167.33
Third Support
1153.56
Zydus Lifesciences Futures & Options
1202.9
10.9 (0.91%)
Zydus Lifesciences Option Chain
View Price, OI, Greeks & More...
23NOV26
1202.40
9.60 (0.80%)
29DEC26
1210.20
9.90 (0.82%)
25JAN27
1215.50
7.30 (0.60%)
ZYDUSLIFE|23NOV26 CE 1200.00
17.45
2.65 (17.91%)
ZYDUSLIFE|23NOV26 PE 1210.00
21.85
-7.6 (-25.81%)
Zydus Lifesciences Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Zydus Lifesciences Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-04 | Quarterly Results |
| 2026-08-11 | Quarterly Results |
| 2026-05-19 | Audited Results |
| 2026-02-09 | Quarterly Results |
| 2025-11-06 | Quarterly Results & Fund raising |
| 2025-08-12 | Quarterly Results |
| 2025-05-20 | Audited Results & Final Dividend |
| 2025-02-05 | Quarterly Results |
| 2024-11-12 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-24 | 2026-07-24 | View More |
| Buyback Period | ||
|---|---|---|
| 4 Jun - 10 Jun 26 12.30 pm | View More |
Zydus Lifesciences News
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences announced that the USFDA conducted an inspection at its LiqMeds facility in the UK from November 9 to 13, 2026. The inspection concluded with 4 observations, which the company intends to address expeditiously.
Nov 14 2026 11:24:17
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Joint Venture
Zydus Lifesciences has completed its transaction to subscribe to a 50% stake in Zydus Sunshine Lifesciences. The transaction, completed on 11 Nov 2026, finalizes its 50:50 joint venture with Sunshine Healthcare Lanka.
Nov 12 2026 07:04:04
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Therapeutics presented positive Phase 2b data for Saroglitazar at AASLD 2026. The trial showed a 39.1% resolution of steatohepatitis in MASH patients receiving the 4mg dose, compared to 13.7% for placebo.
Nov 06 2026 18:57:36
Zydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 4, 2026
Zydus Lifesciences reported its Q2 FY27 financial results with a 29% YoY increase in cons. revenue to ₹7,910 crores. However, the cons. net profit declined by 6% YoY to ₹924 crores. Additionally, the acquisition of Sterling Biotech's API business was completed on November 2, 2026.
Nov 04 2026 12:26:18
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Zydus Lifesciences has successfully completed the acquisition of the API business of Sterling Biotech Limited. The transaction was closed after fulfilling the conditions precedent specified in the Business Transfer Agreement dated 17 September 2024.
Nov 02 2026 12:46:05
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale its next-generation biologics manufacturing platform. The partnership will transition from early development to commercial GMP production, starting with a tech transfer at the 50-liter scale.
Oct 21 2026 18:27:52
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus received final USFDA approval for Estradiol and Levonorgestrel Transdermal System. The drug targets an annual US market size of $45.7 million and is eligible for 180-day CGT exclusivity.
Oct 21 2026 11:12:24
Zydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Half Year Ended On September 30, 2026.
Zydus Life Science board of directors will meet on November 4, 2026, to approve the financial results for the quarter ended September 30, 2026.
Oct 19 2026 12:17:47
Zydus Lifesciences Management
| Name | Position |
|---|---|
| Dhaval N Soni | Company Secretary & Compliance Officer |
| Pankaj R Patel | Chairman |
Zydus Lifesciences Similar Stocks
Divi's Laboratories Ltd.
11093.50
13.50 (0.12%)
Torrent Pharmaceuticals Ltd.
4659.80
-31.40 (0.67%)
Laurus Labs Ltd.
2254.70
34.70 (1.56%)
Lenskart Solutions Ltd.
735.40
0.70 (0.10%)
Apollo Hospitals Enterprise Ltd.
8785.00
14.00 (0.16%)
Dr. Reddy's Laboratories Ltd.
1373.80
-4.10 (0.30%)
Cipla Ltd.
1392.40
-2.10 (0.15%)
Mankind Pharma Ltd.
2635.10
8.50 (0.32%)
Aurobindo Pharma Ltd.
1803.20
9.20 (0.51%)
Max Healthcare Institute Ltd.
1025.65
15.75 (1.56%)
Zydus Lifesciences FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in ZYDUSLIFE
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC